Cutting back the thickets of Biosimilars

The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act (BPCIA) in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

25 October 2017 Introducing more biosimilars could cut healthcare spending by $54 billion over the next ten years, a figure far higher than initially thought, a think tank and research organisation has claimed.

Americas

Amgen and Daiichi Sankyo ink biosimilar agreement

15 July 2016 Biotechnology company Amgen and Japan-based Daiichi Sankyo have agreed a deal that will allow for the commercialisation of nine biosimilars in Japan.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Cutting back the thickets of Biosimilars

More on this story

Editor's picks

Editor's picks

More features